Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

September 22, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 22, 2016-- Syros Pharmaceuticals (NASDAQ: SYRS) announced today that the first patient has been dosed in the Phase 2 clinical trial of its lead drug candidate, SY-1425,…
READ MORE

T2 Biosystems Announces $40 Million Equity Investment by Partner Canon U.S.A.

September 22, 2016
LEXINGTON, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the purchase by Canon U.S.A., of…
READ MORE

Spirox Announces Positive Clinical Study Results for LATERA Implant in Patients with Nasal Valve Collapse, a Major Cause of Nasal Obstruction

September 19, 2016
MENLO PARK, Calif.--(BUSINESS WIRE)--Spirox™, Inc., a company committed to transforming treatment of nasal obstruction, today announced positive results from a prospective, multi-center study of the LATERA™ Absorbable Nasal Implant. The…
READ MORE
more news